6533b7dcfe1ef96bd12727ef
RESEARCH PRODUCT
Updated results of the PARP1/2 inhibitor pamiparib in combination with low-dose (ld) temozolomide (TMZ) in patients (pts) with locally advanced or metastatic solid tumours
J. EvansLisa G. HorvathA. StradellaHaeseong ParkRuth PlummerAmy PrawiraMatthew D. GalskySanjay GoelMelissa Lynne JohnsonL. Fariñas MadridEmiliano CalvoH.-t. ArkenauS.r. ChandanaLinda MileshkinS. MuC. Andreu-vieyraVictor MorenoM. BarveAndrés CervantesR.j. Pelhamsubject
Oncologymedicine.medical_specialtyTemozolomideSurrogate endpointbusiness.industryCancerHematologyNeutropeniamedicine.diseaseChemotherapy regimenPoly (ADP-Ribose) Polymerase Inhibitorchemistry.chemical_compoundOncologychemistryResponse Evaluation Criteria in Solid TumorsInternal medicinemedicineRucaparibbusinessmedicine.drugyear | journal | country | edition | language |
---|---|---|---|---|
2019-10-01 | Annals of Oncology |